The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis
Open accessAbstract
CONTEXT: Presence of low-frequency, or minority, human immunodeficiency virus type 1 (HIV-1) drug resistance mutations may adversely affect response to antiretroviral treatment (ART), but evidence regarding the effects of such mutations on the effectiveness of first-line ART is conflicting. OBJECTIVE: To evaluate the association of preexisting drug-resistant HIV-1 minority variants with risk of first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral virologic failure. DATA SOURCES: Systematic review of published and unpublished studies in PubMed (1966 through December 2010), EMBASE (1974 through December 2010), conference abstracts, and article references. Authors of all studies were contacted for detailed laboratory, ART, and adherence data. STUDY SELECTION AND DATA ABSTRACTION: Studies involving ART-naive participants initiating NNRTI-based regimens were included. Participants were included if all drugs in their ART regimen were fully active by standard HIV drug resistance testing. Cox proportional hazard models using pooled patient-level data were used to estimate the risk of virologic failure based on a Prentice weighted case-cohort analysis stratified by study. DATA SYNTHESIS: Individual data from 10 studies and 985 participants were available for the primary analysis. Low-frequency drug resistance mutations were detected in 187 participants, including 117 of 808 patients in the cohort studies. Low-frequency HIV-1 drug resistance mutations were associated with an increased risk of virologic failure (hazard ratio (HR], 2.3 [95% confidence interval {CI}, 1.7-3.3]; P < .001) after controlling for medication adherence, race/ethnicity, baseline CD4 cell count, and plasma HIV-1 RNA levels. Increased risk of virologic failure was most strongly associated with minority variants resistant to NNRTIs (HR, 2.6 [95% CI, 1.9-3.5]; P < .001). Among participants from the cohort studies, 35% of those with detectable minority variants experienced virologic failure compared with 15% of those without minority variants. The presence of minority variants was associated with 2.5 to 3 times the risk of virologic failure at either 95% or greater or less than 95% overall medication adherence. A dose-dependent increased risk of virologic failure was found in participants with a higher proportion or quantity of drug-resistant variants. CONCLUSION: In a pooled analysis, low-frequency HIV-1 drug resistance mutations, particularly involving NNRTI resistance, were significantly associated with a dose-dependent increased risk of virologic failure with first-line ART.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Case-Cohort Designs
Barlow, W. E., Ichikawa, L., Rosner, D., & Izumi, S. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00102-x · Cited by 682
Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C., Buono, D., Eckholdt, H., Howard, A. A., & Schoenbaum, E. E. (2001) · Clinical Infectious Diseases · doi:10.1086/323201 · Cited by 637
Simen, B. B., Simons, J. F., Hullsiek, K. H., Novak, R. M., MacArthur, R. D., Baxter, J. D., Huang, C., Lubeski, C., Turenchalk, G. S., Braverman, M. S., et al. (2009) · Journal of Infectious Diseases · doi:10.1086/596736 · Cited by 392
Adherence to Nonnucleoside Reverse Transcriptase Inhibitor–Based HIV Therapy and Virologic Outcomes
Nachega, J. B., Hislop, M., Dowdy, D. W., Chaisson, R. E., Regensberg, L., & Maartens, G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00007 · Cited by 374
Johnson, J. A., Li, J.-F., Wei, X., Lipscomb, J., Irlbeck, D., Craig, C., Smith, A., Bennett, D. E., Monsour, M., Sandstrom, P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050158 · Cited by 371
Self-citationLima, V. D., Harrigan, R., Bangsberg, D. R., Hogg, R. S., Gross, R., Yip, B., & Montaner, J. S. G. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819675e9 · Cited by 304
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men
Li, H., Bar, K. J., Wang, S., Decker, J. M., Chen, Y., Sun, C., Salazar-Gonzalez, J. F., Salazar, M. G., Learn, G. H., Morgan, C. J., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000890 · Cited by 297
Little, S. J., Frost, S. D. W., Wong, J. K., Smith, D. M., Pond, S. L. K., Ignacio, C. C., Parkin, N. T., Petropoulos, C. J., & Richman, D. D. (2008) · Journal of Virology · doi:10.1128/jvi.02579-07 · Cited by 251
Metzner, K. J., Giulieri, S. G., Knoepfel, S. A., Rauch, P., Burgisser, P., Yerly, S., Günthard, H. F., & Cavassini, M. (2009) · Clinical Infectious Diseases · doi:10.1086/595703 · Cited by 212
Paredes, R., Lalama, C. M., Ribaudo, H. J., Schackman, B. R., Shikuma, C., Giguel, F., Meyer, W. A., Johnson, V. A., Fiscus, S. A., D’Aquila, R. T., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/650543 · Cited by 204
Wide Variation in the Multiplicity of HIV-1 Infection among Injection Drug Users
Bar, K. J., Li, H., Chamberland, A., Tremblay, C., Routy, J. P., Grayson, T., Sun, C., Wang, S., Learn, G. H., Morgan, C. J., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00077-10 · Cited by 196
Ribaudo, H. J., Liu, H., Schwab, M. G., Schaeffeler, E., Eichelbaum, M. F., Motsinger‐Reif, A. A., Ritchie, M. D., Zanger, U. M., Acosta, E. P., Morse, G. D., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/655470 · Cited by 137
Lataillade, M., Chiarella, J., Yang, R., Schnittman, S., Wirtz, V., Uy, J. P., Seekins, D. W., Krystal, M., Mancini, M., McGrath, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010952 · Cited by 135
Metzner, K. J., Bonhoeffer, S., Fischer, M., Karanicolas, R., Allers, K., Joos, B., Weber, R. K., Hirschel, B. J., Kostrikis, L. G., Günthard, H. F., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/379215 · Cited by 133
Minority Variants of Drug‐Resistant HIV
Gianella, S., & Richman, D. D. (2010) · The Journal of Infectious Diseases · doi:10.1086/655397 · Cited by 99
Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy
Peuchant, O., Thiébaut, R., Capdepont, S., Aurillac-Lavignolle, V., Neau, D., Morlat, P., Dabis, F., Fleury, H. J., & Masquelier, B. (2008) · AIDS · doi:10.1097/qad.0b013e3283034953 · Cited by 98
Goodman, D. D., Zhou, Y., Margot, N., McColl, D. J., Zhong, L., Borroto–Esoda, K., Miller, M. D., & Svarovskaia, E. S. (2010) · AIDS · doi:10.1097/qad.0b013e3283427dcb · Cited by 96
Paredes, R., Marconi, V. C., Campbell, T., & Kuritzkes, D. R. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2007.06.012 · Cited by 72
Metzner, K. J., Rauch, P., von Wyl, V., Leemann, C., Grube, C., Kuster, H., Böni, J., Weber, R. K., & Günthard, H. F. (2010) · The Journal of Infectious Diseases · doi:10.1086/651136 · Cited by 69
Geretti, A. M., Fox, Z. V., Booth, C. L., Smith, C. J., Phillips, A. N., Johnson, M. A., Jin-fen, L., Heneine, W., & Johnson, J. A. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181ba11e8 · Cited by 64
Transmission of HIV‐1 Drug‐Resistant Variants: Prevalence and Effect on Treatment Outcome
Jakobsen, M. R., Tolstrup, M., Søgaard, O. S., Jørgensen, L. B., Gorry, P. R., Laursen, A. L., & Østergaard, L. J. (2010) · Clinical Infectious Diseases · doi:10.1086/650001 · Cited by 64
Schackman, B. R., Ribaudo, H. J., Krambrink, A., Hughes, V., Kuritzkes, D. R., & Gulick, R. M. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815ac499 · Cited by 63
EXTERNAL COMPARISONS WITH THE CASE-COHORT DESIGN
Wacholder, S., & Boivin, J. (1987) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114759 · Cited by 63
Metzner, K. J., Rauch, P., Braun, P., Knechten, H., Ehret, R., Korn, K., Kaiser, R., Sichtig, N., Ranneberg, B., van Lunzen, J., et al. (2010) · Journal of Clinical Virology · doi:10.1016/j.jcv.2010.10.001 · Cited by 53
Balduin, M., Oette, M., Däumer, M., Hoffmann, D. E., Pfister, H., & Kaiser, R. (2009) · Journal of Clinical Virology · doi:10.1016/j.jcv.2009.03.002 · Cited by 52
Charpentier, C., Laureillard, D., Piketty, C., Tisserand, P., Batisse, D., Karmochkine, M., Si‐Mohamed, A., & Weiss, L. (2010) · AIDS · doi:10.1097/qad.0b013e3283367796 · Cited by 45
Antiretroviral Prescribing Patterns in Treatment-Naïve Patients in the United States
McKinnell, J. A., Willig, J. H., Westfall, A. O., Nevin, C. R., Allison, J. J., Raper, J. L., Mugavero, M. J., & Saag, M. S. (2010) · AIDS Patient Care and STDs · doi:10.1089/apc.2009.0220 · Cited by 29
An update on the use of Atripla® in the treatment of HIV in the United States
Horberg, M. A., & Klein, D. B. (2010) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s6366 · Cited by 13
Cited by
Routine Use of Microbial Whole Genome Sequencing in Diagnostic and Public Health Microbiology
Köser, C. U., Ellington, M. J., Cartwright, E. J. P., Gillespie, S. H., Brown, N. M., Farrington, M., Holden, M. T. G., Dougan, G., Bentley, S. D., Parkhill, J., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002824 · Cited by 544
Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID
Jabara, C. B., Jones, C. D., Roach, J., Anderson, J. A., & Swanstrom, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110064108 · Cited by 365
HIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
Emerging Technologies for the Clinical Microbiology Laboratory
Buchan, B. W., & Ledeboer, N. A. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00003-14 · Cited by 297
Multifunctional antimicrobial materials: From rational design to biomedical applications
Duan, S., Wu, R., Xiong, Y.-H., Ren, H.-M., Lei, C., Zhao, Y.-Q., Zhang, X.-Y., & Xu, F.-J. (2022) · Progress in Materials Science · doi:10.1016/j.pmatsci.2021.100887 · Cited by 257
Metadata
- Authors
- Li, J. Z.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-04-06
- Volume
- 305
- Issue
- 13
- Pages
- 1327
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2139311359
- Cited by
- 367
- References
- 28
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.